Search found 2904 matches

by MSUK
Mon Mar 05, 2018 8:27 am
Forum: Campath (Lemtrada, Alemtuzumab)
Topic: Third course of Lemtrada improves MS patient’s relapse rate
Replies: 0
Views: 2489

Third course of Lemtrada improves MS patient’s relapse rate

Study shows third course of Lemtrada improves MS patient’s relapse rate and disability A study released at #ACTRIMS2018 has revealed that patients who experienced relapses after two courses of Lemtrada (alemtuzumab) showed improvement in relapse rate and disability progression after a third course o...
by MSUK
Fri Mar 02, 2018 6:45 am
Forum: General Discussion
Topic: Daclizumab (Zinbryta) is withdrawn from the European market
Replies: 1
Views: 799

Daclizumab (Zinbryta) is withdrawn from the European market

Germany recently informed the European Medicines Agency (EMA) that seven patients with multiple sclerosis (MS) had developed immune-mediated inflammation of the brain (encephalitis) during treatment with daclizumab beta (Zinbryta). Three of these patients also had a severe allergic reaction (drug re...
by MSUK
Fri Mar 02, 2018 3:00 am
Forum: General Discussion
Topic: Eating fish may be tied to a reduced risk of MS
Replies: 2
Views: 864

Eating fish may be tied to a reduced risk of MS

Eating fish at least once a week or eating fish one to three times per month in addition to taking daily fish oil supplements may be associated with a reduced risk of multiple sclerosis (MS), according to a preliminary study released that will be presented at the American Academy of Neurology's 70th...
by MSUK
Tue Feb 27, 2018 2:20 am
Forum: General Discussion
Topic: Progress on the legalisation of medical cannabis...
Replies: 2
Views: 815

Progress on the legalisation of medical cannabis...

Progress on the legalisation of medical cannabis takes a side step On Friday 23 February, the United Patients Alliance gathered for another peaceful protest outside the House of Parliament while the second reading of the Emily Brice bill took place…Read more - http://www.ms-uk.org/progress-legalisat...
by MSUK
Wed Feb 21, 2018 4:54 am
Forum: General Discussion
Topic: Study - 93.7% improvement in patients treated with cannabis
Replies: 0
Views: 932

Study - 93.7% improvement in patients treated with cannabis

Study highlights 93.7% improvement in patients treated with cannabis In recent years there has been a substantial increase in the use of medical cannabis, particularly with the aging population. In a recent study, titled “Epidemiological characteristics, safety and efficacy of medical cannabis in th...
by MSUK
Tue Feb 20, 2018 5:44 am
Forum: Tysabri (Antegren or Natalizumab)
Topic: Risks associated between MS drug natalizumab and pregnancy
Replies: 0
Views: 1414

Risks associated between MS drug natalizumab and pregnancy

Study reveals the risks associated between MS drug natalizumab and pregnancy A recent study, published in the journal Neurology, assessed foetal risk after pregnancy exposure to natalizumab (Tysabri) in women with multiple sclerosis (MS). The Italian study specifically focused on spontaneous abortio...
by MSUK
Wed Feb 14, 2018 6:13 am
Forum: General Discussion
Topic: Higher dose of MS drug Glatopa finally gets US approval
Replies: 0
Views: 883

Higher dose of MS drug Glatopa finally gets US approval

Sandoz, a Novartis division, has announced US Food and Drug Administration (FDA) approval and launched a 40 mg/ml dose of Glatopa, a glatiramer acetate injection…Read more - http://www.ms-uk.org/higher-dose-ms-drug-glatopa-finally-gets-us-approval https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/261688...
by MSUK
Wed Feb 14, 2018 6:11 am
Forum: Mavenclad (Cladribine)
Topic: Cladribine gets approval in Scotland
Replies: 0
Views: 874

Cladribine gets approval in Scotland

NHS Scotland has accepted cladribine (Mavenclad) as a treatment option for people with highly active multiple sclerosis (MS) living in Scotland… http://www.ms-uk.org/cladribine-gets-approval-scotland https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/26168845_1680181818687432_2707888596679484414_n.png?oh...
by MSUK
Tue Feb 13, 2018 5:17 am
Forum: General Discussion
Topic: Experimental therapy restores nerve insulation damage
Replies: 0
Views: 900

Experimental therapy restores nerve insulation damage

Experimental therapy restores nerve insulation damage caused by autoimmune conditions When the body attacks its own healthy tissues in an autoimmune condition, peripheral nerve damage disable people and causes persistent neuropathic pain when insulation on healing nerves doesn't fully regenerate…Rea...
by MSUK
Wed Feb 07, 2018 3:21 am
Forum: Tysabri (Antegren or Natalizumab)
Topic: Changing natalizumab dosing frequency reduced risk for PML
Replies: 1
Views: 1484

Changing natalizumab dosing frequency reduced risk for PML

Changing natalizumab dosing frequency reduced risk for Progressive Multifocal Leukoencephalopathy (PML) A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS sp...
by MSUK
Wed Feb 07, 2018 1:28 am
Forum: General Discussion
Topic: Family Planning among Women with Relapsing MS
Replies: 0
Views: 743

Family Planning among Women with Relapsing MS

Survey Highlights Misconceptions about Family Planning among Women with Relapsing Forms of Multiple Sclerosis Of 1,000 women diagnosed with relapsing remitting multiple sclerosis (RRMS) in the last five years, 88% were concerned they would not be able to have children, despite studies that show othe...
by MSUK
Fri Feb 02, 2018 5:51 am
Forum: General Discussion
Topic: Ibudilast 26% reduction in confirmed disability progression
Replies: 0
Views: 772

Ibudilast 26% reduction in confirmed disability progression

MS drug ibudilast demonstrated a 26% reduction in confirmed disability progression in progressive MS trial Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS)...Read more...
by MSUK
Thu Feb 01, 2018 7:29 am
Forum: General Discussion
Topic: Balance and eye-movement exercises could help people with MS
Replies: 0
Views: 751

Balance and eye-movement exercises could help people with MS

According to a study, published in the 31 January 2018 online edition of Neurology, the medical journal of the American Academy of Neurology, a special programme of balance and eye movement exercises may help people with multiple sclerosis (MS)... Read more - http://www.ms-uk.org/balance-and-eye-mov...
by MSUK
Mon Jan 29, 2018 1:44 am
Forum: General Discussion
Topic: Holland approves cannabis chewing gum development programme
Replies: 0
Views: 992

Holland approves cannabis chewing gum development programme

The Dutch Medicines Evaluation Board has signed off AXIM Biotechnologies’ MedChew Rx clinical development programme, which will see them develop and trial a cannabis based chewing gum…Read more - http://www.ms-uk.org/holland-approves-cannabis-chewing-gum-development-programme https://scontent-lht6-1...
by MSUK
Thu Jan 25, 2018 6:54 am
Forum: Gilenya
Topic: Gilenya withdrawal may trigger the return of disease act.
Replies: 0
Views: 3884

Gilenya withdrawal may trigger the return of disease act.

Gilenya withdrawal may trigger the return of pre-treatment disease activity It is difficult to identify patients at risk of disease reactivation. So in a recent study scientists at Cerrahpasa School of Medicine, Istanbul University in Turkey compared the demographic and clinical features of patients...